Auto-generated from public data. Not the firm's stated position.
Based on disclosed data, Debiopharm Innovation Fund appears to focus on early-stage healthtech companies that leverage AI and data technologies to address clinical and operational challenges in drug development and oncology. Recent portfolio suggests an investment thesis centered on digital therapeutics and privacy-preserving data solutions that enhance clinical trial efficiency and patient outcomes.
Generated 18 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Oct 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.